Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
Clinical trial NCT00171899 · COMPLETED
Trial details
- NCT number
- NCT00171899
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2005-04-01
- Primary completion
- 2007-06-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.